In a 24-year-old patient with ulcerative colitis and primary sclerosing cholangitis on adalimumab (Humira), are persistent fatigue, mild facial swelling, eyelid edema, and fever six days after the second dose of Shingrix (recombinant zoster vaccine) expected, and how should they be managed?

Shingrix Adverse Reactions at 6 Days Post-Vaccination

The symptoms your patient is experiencing—persistent fatigue, mild facial swelling, eyelid edema, and the initial high fever—are consistent with known adverse reactions to Shingrix, though the duration at 6 days is approaching the upper limit of expected reactogenicity. Most Shingrix reactions resolve within 2-3 days, but symptoms can persist up to 7 days according to FDA labeling data 1.

Expected Adverse Reactions

The FDA label for Shingrix documents that in clinical trials 1:

• Systemic reactions are common and expected: Fatigue (45%), fever (21%), and myalgia (45%) were frequently reported
• Fever of 39.4°C is within the severe range but occurred in clinical trials (Grade 3 fever defined as >39.0°C occurred in 0.4-1% of vaccinated subjects)
• Median duration of reactions is 2-3 days, with monitoring conducted for 7 days post-vaccination
• Second dose reactions can be more severe: Headache and shivering were more frequent after dose 2 (28% and 21%) compared to dose 1 (24% and 14%)

Concerning Features Requiring Evaluation

While most symptoms align with expected vaccine reactions, the facial swelling and eyelid edema warrant closer attention:

Immediate Assessment Needed:

• Rule out hypersensitivity reaction: The FDA label specifically lists angioedema, rash, and urticaria as postmarketing adverse reactions 1
• Assess for airway involvement: Any tongue swelling, throat tightness, or breathing difficulty requires emergency evaluation
• Examine for rash or urticaria: These would suggest allergic rather than inflammatory response

Red Flags to Exclude:

• Guillain-Barré Syndrome (GBS): The absence of paresthesia is reassuring, but GBS has been associated with Shingrix in postmarketing surveillance (3 excess cases per million doses, primarily after first dose) 1
  • Monitor for: ascending weakness, sensory changes, difficulty walking, facial weakness
  • Risk window: 1-42 days post-vaccination
• Decreased arm mobility: Can persist for >1 week per FDA data but should be localized to injection site 1

Management Algorithm

If Hypersensitivity Features Present (facial swelling, eyelid edema):

1. Immediate evaluation for angioedema vs. inflammatory edema
2. Antihistamines (e.g., cetirizine 10mg daily or diphenhydramine 25-50mg every 6 hours)
3. Consider short course of oral corticosteroids if significant facial swelling (e.g., prednisone 40-60mg daily for 3-5 days)
4. Do NOT administer further doses if true hypersensitivity confirmed

If Standard Reactogenicity (fatigue, weakness without allergic features):

1. Supportive care: Rest, hydration, acetaminophen or NSAIDs for symptom relief
2. Reassurance: Symptoms should resolve by day 7
3. Re-evaluate if symptoms persist beyond 7 days or worsen
4. Monitor for GBS symptoms through day 42

For This Specific Patient on Adalimumab:

• The immunosuppression from Humira does not contraindicate Shingrix (it's a non-live vaccine) 2, 3
• IBD patients have 1.4-1.74x increased risk of herpes zoster, further elevated by anti-TNF therapy 3
• Shingrix is preferred over live zoster vaccine in immunosuppressed patients 3
• No evidence that adalimumab increases vaccine reaction severity, though immunogenicity may be slightly reduced

Critical Pitfalls to Avoid

1. Don't dismiss facial swelling as "normal": While periorbital edema can occur with systemic inflammatory responses, true angioedema requires intervention
2. Don't attribute all symptoms to UC/PSC flare: The temporal relationship to vaccination is too close
3. Don't withhold evaluation due to young age: While Shingrix is typically given ≥50 years, this patient appropriately received it due to immunosuppression 3
4. Monitor liver enzymes: Given PSC history, ensure hepatic function remains stable (though vaccine-related hepatotoxicity is not documented)

When to Escalate Care

Seek immediate evaluation if:

• Progressive facial/tongue swelling
• Respiratory symptoms develop
• New neurological symptoms (weakness, numbness, gait changes)
• Symptoms worsen after day 6 or persist beyond day 10
• High fever recurs

The bottom line: Most likely this represents robust but expected vaccine reactogenicity that should resolve within 1-2 more days, but the facial swelling requires active assessment to exclude hypersensitivity reaction. The patient's immunosuppressed state makes Shingrix appropriate and important for herpes zoster prevention, but also necessitates closer monitoring of adverse reactions.